Ahmed Ibrahim: Optimal Antithrombotic Therapy for Secondary Stroke Prevention in Patients with AF and ASCVD
Ahmed Ibrahim, Medical Student at Alexandria University, shared a post on LinkedIn about a recent article that he and his colleagues co-authored:
“For patients with ischemic stroke and comorbid Atrial Fibrillation (AF) and Atherosclerotic Cardiovascular Disease (ASCVD), does adding an antiplatelet to an anticoagulant do more harm than good in secondary stroke prevention?
Key Findings from our Network Meta-Analysis (should be interpreted with caution and contextualized within the study’s limitations):
The Power of One: OAC monotherapy emerged as the most favorable strategy for secondary prevention. It provides a balanced profile, offering strong protection against recurrent strokes with potential lower risk of major bleeding compared to combination therapy.
Less is More: Adding antiplatelet therapy (APT) to an anticoagulant did not provide additional clinical benefit. It may increase the risk of major bleeding without significantly reducing the risk of further ischemic events or death.
APT Alone: While APT monotherapy had the lowest bleeding risk, it was associated with a concerning trend toward increased all-cause mortality and was the least effective at preventing recurrent ischemic strokes.
Take-Home Message:
- In secondary stroke prevention for patients with AF and ASCVD, OAC monotherapy appears to offer a favorable balance between efficacy and safety.
- While combination therapy may be considered in select cases with compelling indications, routine use of antiplatelet therapy alongside anticoagulation should be approached with caution due to potential increased bleeding risk without clear added benefit.
Grateful to my colleagues Elsayed Balbaa, Ameer Awashra, Abdalhakim Shubietah, Giulia Cavolina, Alessio villari.
Heartfelt thanks to our seniors, Prof. Giuseppe Andò and Dr. Pierre F. Sabouret, for their invaluable support and guidance.”
Title: Optimal antithrombotic therapy for post-ischemic stroke patients with atrial fibrillation and atherosclerotic cardiovascular disease: A frequentist network meta-analysis
Authors: Ahmed Ibrahim, Elsayed Balbaa, Ameer Awashra, Abdalhakim Shubietah, Giulia Cavolina, Alessio Villari, Giuseppe Andò, Pierre Sabouret
Read Full Article on Journal of the Neurological Sciences.
Stay updated with Hemostasis Today.
-
Nov 9, 2026, 09:29Veronica Sanchez: A Framework for Woman’s Health
-
Nov 8, 2026, 19:31Anna Kajaste-Rudnitski: Presenting AAV-Induced p53 Signalling in Human CNS Cells at ESGCT 26
-
Nov 8, 2026, 19:29David McIntosh: Cybersecurity Matters, but Blood Availability Remains the Bigger Challenge
-
Nov 8, 2026, 19:26Wenxue Ma: An Integrative Framework for Macrophage-Mediated Therapeutic Resistance in Cancer
-
Nov 8, 2026, 19:25Yildiz Yigit: Presenting a Polycythemia Vera Case at the MPN Subcommittee Session
-
Nov 8, 2026, 18:56Denis Oduor: Strengthening the Regulation and Delivery of Blood Transfusion and Transplantation Services
-
Nov 8, 2026, 18:28Raghavendra Rao: A Narrative Review on Chronic Venous Disease during Pregnancy
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause